fashion -WSS

fashion

author：leisure time 2025-09-03 05:29:44 - browse：52783

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Medicare Advantage overpayments discussion gets experts fired up

WSS

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Syphilis numbers in the United States reach record heights

Life science postdocs should get big pay hike, NIH panel says

Why you shouldn’t ask, “What country has the best health care?”

Allen Institute goes after foundational questions, CEO Costa says

Philips to halt sales of sleep apnea machines in U.S.

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Hollywood unions extend contract negotiations for actors

Wegovy leads to weight loss. Can it treat depression, too?

After affirmative action ruling, medical educators look to 'holistic review'

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

New clues to why women have higher risk of autoimmune disorders

Wildfire smoke exposes gaps in outdoor worker protections

New clues to why women have higher risk of autoimmune disorders

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Profiling embryos to choose those with higher IQs is almost a reality

Wikipedia

Physician assistants need a new name. Here's what it should be

Medicare Advantage insurers face 0.2% cut to 2025 payments

Reconstructing family trees of blood cells may help predict disease

Merck to acquire Harpoon Therapeutics for $680 million

At JPM 2024, hospital systems pitch financial strength to investors

Bernie Sanders is gearing up to subpoena pharma CEOs

explore

knowledge

hotspot

hotspot